Skip to content
Subscriber Only

EpiPen Competitor Will Re-Launch After Being Pulled Off Market

  • Kaleo says it hasn’t settled on pricing for the device
  • Auvi-Q was previously recalled for suspected malfunctions

Mylan NV’s dominance of the U.S. allergy-shot market will be challenged next year as drugmaker Kaleo Inc. says it will resume sales of a competing product that was recalled last year.

Kaleo’s injector, called Auvi-Q, was recalled from U.S. sales about a year ago over potential malfunctions that could give patients the wrong dose of drug. Closely-held Kaleo said in a statement Wednesday that the shot will return to the market in the first half of 2017. It hasn’t settled on a price, said Chief Executive Officer Spencer Williamson in a phone interview.